Popular pre-market trades in US stocks: Rectitude up 17.30% in pre-market; Scribe Therapeutics up 14.12% in pre-market

Pre-market Hot Trades in US Stocks

Rectitude is up 17.30% in pre-market trading. Based on recent key news:

1. On July 30, Rectitude Holdings Ltd announced its financial performance for the fiscal year 2026. The company's report showed strong performance for the fiscal year ending March 31, 2026, driving the stock price up.

2. On July 30, the U.S. Securities and Exchange Commission released documents regarding Rectitude Holdings Ltd, further confirming the company's financial status and boosting investor confidence.

3. On July 31, market analysts suggested focusing on companies that solve real problems, with Rectitude Holdings Ltd being considered one of them, attracting more investor attention. The industrial safety equipment sector has performed strongly recently.

Scribe Therapeutics is up 14.12% in pre-market trading. Based on recent key news:

1. On July 30, OrbiMed Advisors increased its indirect common stock holdings in Scribe Therapeutics to 1,348,825 shares and acquired 1 million shares at $15 each. This news indicates increased investor confidence in the company's future, driving the stock price up.

2. On July 30, Eli Lilly stated that it may hire consultants, but currently has no specific plans to change Scribe's operations. This indicates market attention to the company's future strategy, which may affect investor sentiment.

3. On July 29, OrbiMed's investment activities in the biotechnology sector were disclosed, supporting innovative drug developers and further enhancing market confidence in Scribe. Investment activities in the biotechnology sector have been active recently, with significant capital inflows.

Top Gainers in Pre-market US Stocks

WeBus is up 199.67% in pre-market trading. Based on recent key news:

1. On July 30, Wetour Robotics announced a stock consolidation plan with a consolidation ratio of 1 to 100. This move aims to improve the market liquidity and attractiveness of the stock, expected to take effect on August 3. This news may trigger positive expectations for the company's future development, driving the stock price up.

2. On July 29, Fermi and Galaxy Digital faced challenges amid changes in cryptocurrency regulation, leading to fluctuations in investor interest in risk assets. In this context, investors may turn to other high-growth potential companies like Wetour Robotics, resulting in significant stock price volatility.

3. On July 29, the SEC reminded investors to be cautious about forward-looking statements, emphasizing other factors discussed in the company's SEC filings. Such warnings may prompt investors to reassess their portfolios, increasing attention to Wetour Robotics. Changes in cryptocurrency regulation affect market sentiment K Wave Media pre-market rose 138.46%. Based on recent key news:

4. On July 30, K Wave Media announced a 1-for-30 reverse stock split. This move aims to meet Nasdaq's minimum bid requirements and is expected to take effect on August 3. The reverse split will reduce the number of shares outstanding, thereby increasing the price per share.

5. On July 30, K Wave Media plans to trade on Nasdaq at an adjusted price. This move will proportionally raise the price per share, although it remains subject to market fluctuations.

6. On July 30, K Wave Media issued a statement emphasizing that future events may lead to changes in its assessment, but it does not undertake the obligation to update forward-looking statements. The market reacted positively to the reverse split, causing a significant rise in stock price.

Replimune pre-market rose 124.95%. Based on recent key news:

1. On July 30, Replimune announced favorable results from the FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting, supporting the application for RP1 in advanced melanoma. This news drove a substantial increase in stock price.

2. On July 28, FDA reviewers expressed concerns about Replimune's RP1 drug trial, stating that the trial data was insufficient to demonstrate the drug's efficacy, leading to a pre-market decline in stock price.

3. On July 30, Replimune announced that the FDA's target action date is August 2, with the expectation that accelerated approval for RP1 is almost certain, further boosting market confidence. The market remains attentive to regulatory risks in biotech stocks